After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells.
Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved …

Glioma is the most common primary cancer of the central nervous system, and around 50%
of patients present with the most aggressive form of the disease, glioblastoma. Conventional …

Mobilizing antitumour immunity through vaccination potentially constitutes a powerful
anticancer strategy but has not yet provided robust clinical benefits in large patient …

With the understanding of the complex interaction between the tumour microenvironment
and immunotherapy, there is increasing interest in the role of immune regulators in the …

Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor
and remains a therapeutic challenge: even after multimodal therapy, median survival of …

Glioblastoma (GBM) is the most devastating brain tumor, with associated poor prognosis.
Despite advances in surgery and chemoradiation, the survival of afflicted patients has not …

Background. Adaptive immune resistance in the tumor microenvironment appears to
attenuate the immunotherapeutic targeting of glioblastoma (GBM). In this study, we identified …

Glioblastoma multiforme (GBM) is the most frequently occurring primary brain tumor and has
a very poor prognosis, with only around 5% of patients surviving for a period of 5 years or …